Humanigen to Present at Upcoming Investor Conferences
October 27 2020 - 4:01PM
Business Wire
Humanigen, Inc., (Nasdaq: HGEN) (“Humanigen”), a clinical
stage biopharmaceutical company focused on preventing and treating
an immune hyper-response called ‘cytokine storm’ with its lead drug
candidate lenzilumab™, today announced that the Company’s
management will present or participate in panel discussions at the
following upcoming virtual investor conferences:
ROTH Capital Healthcare Event – COVID-19 Therapeutics in
Development (October 28, 2020) Date: Wednesday, October 28 Panel
series: Immune Modulators to Ameliorate COVID Sequelae 2 Panel
time: 9:00 AM ET Registration link:
https://roth.zoom.us/webinar/register/WN_FF_LgnOeQmm7VsRye97DtQ
Bryan, Garnier & Co European Healthcare Conference (November
16-17, 2020) Date: Monday, November 16 For more information:
https://www.bryangarnier.com/home/sectors/healthcare/
Stifel Virtual Healthcare Conference (November 16-18, 2020)
Date: Tuesday, November 17 Presentation time: 1:20 PM ET Live
webcast link: https://wsw.com/webcast/stifel27/hgen/2071712
Jefferies London Healthcare Conference (November 17-19, 2020)
Date: Thursday, November 19 Presentation time: 6:45 PM GMT (2:45 PM
ET) Live webcast link:
https://wsw.com/webcast/jeff141/hgen/1826850
The conferences are being held in a virtual format. A live
webcast of the presentation may be accessed on the Events section
of the Humanigen website https://www.humanigen.com/events. Archived
replay will be available on the Company website for 30 days
following the event.
About Humanigen, Inc.
Humanigen, Inc. is developing its portfolio of clinical and
pre-clinical therapies for the treatment of cancers and infectious
diseases via its novel, cutting-edge GM-CSF neutralization and
gene-knockout platforms. We believe that our GM-CSF neutralization
and gene-editing platform technologies have the potential to reduce
the inflammatory cascade associated with coronavirus infection. The
company’s immediate focus is to prevent or minimize the cytokine
storm that precedes severe lung dysfunction and ARDS in serious
cases of SARS-CoV-2 infection. The company is also focused on
creating next-generation combinatory gene-edited CAR-T therapies
using strategies to improve efficacy while employing GM-CSF gene
knockout technologies to control toxicity. In addition, the company
is developing its own portfolio of proprietary first-in-class
EphA3-CAR-T for various solid cancers and EMR1-CAR-T for various
eosinophilic disorders. The company is also exploring the
effectiveness of its GM-CSF neutralization technologies (either
through the use of lenzilumab™ as a neutralizing antibody or
through GM-CSF gene knockout) in combination with other CAR-T,
bispecific or natural killer (NK) T cell engaging immunotherapy
treatments to break the efficacy/toxicity linkage, including to
prevent and/or treat graft-versus-host disease (GvHD) in patients
undergoing allogeneic hematopoietic stem cell transplantation
(HSCT). Additionally, Humanigen and Kite, a Gilead Company, are
evaluating lenzilumab as sequenced therapy with Yescarta®
(axicabtagene ciloleucel) in patients with relapsed or refractory
large B-cell lymphoma in a clinical collaboration. For more
information, visit www.humanigen.com.
Forward-Looking
Statements
This release contains forward-looking statements.
Forward-looking statements reflect management's current knowledge,
assumptions, judgment and expectations regarding future performance
or events. Although management believes that the expectations
reflected in such statements are reasonable, they give no assurance
that such expectations will prove to be correct and you should be
aware that actual events or results may differ materially from
those contained in the forward-looking statements. Words such as
"will," "expect," "intend," "plan," "potential," "possible,"
"goals," "accelerate," "continue," and similar expressions identify
forward-looking statements. Forward-looking statements are subject
to a number of risks and uncertainties including, but not limited
to, the risks inherent in our lack of profitability; our dependence
on partners to further the development of our product candidates;
the costs associated with CMC work and the uncertainties inherent
in the development and launch of any new pharmaceutical product;
the outcome of pending or future litigation; and the various risks
and uncertainties described in the "Risk Factors" sections and
elsewhere in the Company's periodic and other filings with the
Securities and Exchange Commission.
All forward-looking statements are expressly qualified in their
entirety by this cautionary notice. You should not place undue
reliance on any forward-looking statements, which speak only as of
the date of this release. We undertake no obligation to revise or
update any forward-looking statements made in this press release to
reflect events or circumstances after the date hereof or to reflect
new information or the occurrence of unanticipated events, except
as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201027006097/en/
Media Cammy Duong Westwicke, an ICR company
Cammy.duong@westwicke.com 203-682-8380
Investors Alan Lada Solebury Trout
ALada@SoleburyTrout.com 617-221-8006
Humanigen (NASDAQ:HGEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Humanigen (NASDAQ:HGEN)
Historical Stock Chart
From Apr 2023 to Apr 2024